- Home
- Medical Imaging
- Molecular Imaging
- PET/CT Scanners
- Biograph Vision

Biograph VisionSee a whole new world of precision.
Biograph Vision™1 is the next-generation of PET/CT that empowers you to see a whole new world of precision. It goes beyond digital to reveal the bigger picture, maximize efficiency, and help you to better understand disease progression.

AIDAN: The intelligent scanner platform for PET/CT
- Become more efficient
- Personalize your scans
- Standardize your exams
Особливості

Accuracy to reveal the bigger picture

Performance to maximize efficiency

Reproducibility to understand disease progression
Biograph Vision can help reduce unwarranted variations to maximize patient care. Its zero-differential-deflection patient bed provides perfect registration between the CT and PET fields of view, ensuring accurate attenuation correction for more precise quantification. QualityGuard5 automates daily and weekly quality control without a radioactive source to help produce consistent and accurate results. FlowMotion Multiparametric PET Suite makes it easier and faster to perform parametric imaging in daily clinical routine. It is completely automated and integrated into the PET/CT workflow for more reproducible images.

Exclusive bed design and wide bore
3.2-mm LSO crystals
Optiso UDR detector
CT capability
iMAR
SAFIRE
Whole-body dynamic imaging
QualityGuard™
FlowMotion AI™
FAST PET Workflow AI
Multiparametric PET Suite AI
OncoFreeze™ / OncoFreeze AI
Exclusive bed design and wide bore
Zero differential deflection for accurate attenuation correction and TG-66 compliant along with a 78-cm bore to support bariatric imaging and easier positioning of radiation oncology devices
Our customers say...
"…by improving the spatial resolution…you have less partial volume effect, so you get sharper images and more accurate quantification."
Ronald Boellaard, PhD

Ronald Boellaard, PhD
"We have now already, as compared to the older system, reduced the activity we inject… Now it's probably 30% faster with about 30% less dose which is something very acceptable."2

"Being more quantitative, our reproducibility can be that much better, and it may matter when we’re trying to do a repeat scan early on in a therapy and decide what to do."

Videos
Making vision a reality
Watch the full-length documentary video on how Biograph Vision became a reality.
The passion behind the technology
Biograph Vision - Trailer
Biograph Vision - Features
Клінічне використання
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8

Case 1
Normal brain metabolism in a subject with suspected multi-system atrophy
Clinical detail
A 67-year-old male with progressive muscular stiffness, difficulty in swallowing, and autonomic dysfunctions with no response to levodopa therapy; undergoing evaluation for striatal multi-system atrophy. A Fludeoxyglucose F 18 Injection.* (18F FDG) PET/CT scan of the brain was performed on Biograph Vision. The study shows normal uptake in brain with excellent delineation of functioning cortex and sharp contrast between cortex and white matter. Additionally there is sharp basal ganglial edge definition, especially the sharp margins and distinct separation of the head of caudate nucleus and putamen.

Case 1
Normal brain metabolism in a subject with suspected multi-system atrophy
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Clinical detail
A 73-year-old male with prostate cancer treated with brachytherapy presented with biochemical relapse. The patient underwent PET/CT study following injection of androgen receptor imaging agent 18F –dihydrotestosterone (18F-FDHT) in order to assess presence of androgen receptor positive recurrence. PET/CT was performed on Biograph Vision™. Images showed tracer within cardiac and vascular blood pool as well as in the liver. Significant clearance of tracer through the biliary tract and gall bladder, kidneys, and intestines is visualized. No well defined focal uptake suggestive of androgen receptor-avid metastatic lesions is visualized, although primary prostate bed showed significant uptake on higher intensity images. Sharp delineation of vascular structures, especially cavernous and sigmoid sinuses as well as carotid and subclavian vessels reflect the high overall image quality and low noise level in the Biograph Vision images.

Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Examination protocol
Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.

Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Examination protocol
Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.

Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Examination protocol
Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.

Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
Clinical detail
A 78-year-old male with primary prostate cancer underwent 68Ga-PSMA PET/CT initial staging. PET/CT was performed on Biograph Vision™. The images showed high tracer uptake in kidneys, salivary glands, and bladder, which are at physiologically normal levels. The liver, spleen, and intestines also show lower but normal levels of uptake as well. There is also focal hypermetabolism in the prostate reflecting primary tumor and the small hypermetabolic right external iliac lymph node is suggestive of solitary nodal metastases. No other PSMA-avid metastatic lesions are visualized. Sharply delineated renal, salivary gland, bladder, and intestinal margins reflect the high overall image quality and low background noise level in the Biograph Vision images.

Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.

Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.

Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.

Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Clinical detail
A 49-year-old woman with a history of operated ovarian carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision™. The images showed hypermetabolic metastases in the right obturator node, anterior pelvic wall above, and adjacent to the bladder as well as multiple small liver metastases in the posterior aspect of the right lobe (Segment VII) and in the caudate lobe. Sharp delineation of small liver lesions with high contrast compared to normal liver without respiratory gating reflect the overall high image quality and high lesion contrast to background in the Biograph Vision images.

Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

Case 5
Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT
Clinical detail
A 69-year-old male with a history of operated colorectal carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision™. The images showed sharp delineation of small hypermetabolic metastasis in the right lobe of liver near the dome of diaphragm (Segment VII). Intense uptake in the abdominal wall is suggestive of metastatic deposit. Mildly increased uptake in mediastinal lymph nodes are possibly secondary to inflammation. High contrast of small liver metastases without significant motion related blurring even without respiratory gating reflects high overall image quality and increased lesion contrast to background in the Biograph Vision images.

Case 5
Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT
Examination protocol
Biograph Vision, 7.3 mCi (270 MBq) 18F FDG, 1 hour 50 minutes post-injection delay. CT: 100 kV, 10 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
* Indications and Important Safety Information.

Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Clinical detail
A 77-year-old female with a history of breast carcinoma treated with left mastectomy and chemo-radiotherapy presented with pain in the thoracic wall along with pleural effusion. The patient underwent 18F Fluoroestradiol (FES) PET/CT to assess presence of estrogen receptor (ER) positive metastases. A PET/CT was performed on Biograph Vision™. High resolution PET images show faint uptake in the left pleura suggestive of ER positive pleural thickening. The PET/CT images also sharply delineates physiological uptake in the gall bladder and biliary tract and intestine reflecting hepatobiliary clearance of tracer. Sharp definition of biliary tree with high contrast compared to background even at 440 x 440 matrix reconstructed resolution reflect the high overall image quality of Biograph Vision images.

Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) 18F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.

Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) 18F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.

Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Clinical detail
A 79-year-old male with unknown clinical history. A PET/CT was performed on Biograph Vision™. High resolution PET images show sharp delineation of physiological uptake in the aortic walls, atrial walls, carotid, and subclavian vessels. Normal marrow uptake within vertebrae, ribs, and pelvis are well visualized. Physiological uptake in the gastric mucosa and intestines, with note made of sharply delineated descending colon. Sharp delineation of normal structures like rib and vessels with low background uptake reflect high overall image quality even at 440x440 matrix reconstructed resolution of Biograph Vision images.

Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Clinical detail
70-year-old male. Though clinical history unknown, there are obviously multiple metastases as shown on PET/CT performed on the Biograph Vision™. High resolution PET images show multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae and soft tissue. Sharp delineation with high lesion contrast of small metastases in the vertebrae, pelvis, mediastinal nodes and soft tissue especially in the left thigh reflect the high image quality even at 440x440 matrix reconstructed resolution of the Biograph Vision images.

Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Технічні особливості

Transcend digital with the Optiso UDR detector
Optiso UDR’s proprietary 3.2-mm LSO crystals move silicon photomultiplier (SiPM) technology beyond digital to a new level of precision to help you detect small lesions, devise accurate treatment strategies\, and achieve optimal performance in a wide range of count rates.
Take a look inside Biograph Vision

See how Optiso Ultra Dynamic Range (UDR) PET detector advances PET/CT beyond digital.
Технічні характеристики
Gantry | |
Bore diameter | 78 cm |
Tunnel length | 136 cm |
Table capacity | 227 kg (500 lb) |
CT | |
Generator power | 80 kW (100 kW optional) |
Rotation times | 0.33, 0.305, 0.285 s |
Tube voltages | 70, 80, 100, 120, 140 kV |
Iterative reconstruction | SAFIRE5 |
Metal artifact reduction | iMAR5 |
Slices | 64, 128 |
PET | |
Axial field of view | 26.3 cm |
Crystal size | 3.2 x 3.2 x 20 mm |
SiPM coverage of crystal array | 100% |
Effective sensitivity | 100 cps/kBq |
Effective NEC | 1870 kcps |
Time of flight performance | 214 ps |
Ця інформація вам допомогла?
Дякуємо
Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.